← All trials
NCT02229942
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Sep 1, 2017
- Completion date
- Sep 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BergenLead sponsor
- University Hospital of North NorwayCollaborator
- Osaka UniversityCollaborator
- University of BergenOverall official - principal investigator
- Norwegian University of Science and TechnologyCollaborator
- Telemark Hospital TrustCollaborator
- The Kavli FoundationCollaborator
- MEandYou FoundationCollaborator
- The Norwegian ME associationCollaborator
- Government of NorwayCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.